1.
Biomed Pharmacother
; 142: 111980, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1330664
ABSTRACT
One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this "unique" cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.
Subject(s)
COVID-19 Drug Treatment , COVID-19 , Cytokine Release Syndrome , Interleukin-17 , Biomarkers/blood , COVID-19/diagnosis , COVID-19/immunology , Cytokine Release Syndrome/etiology , Cytokine Release Syndrome/immunology , Disease Progression , Drug Discovery , Humans , Inflammation Mediators/metabolism , Interleukin-17/blood , Interleukin-17/immunology , Severity of Illness Index
2.
Pharmacol Res
; 156: 104791, 2020 06.
Article
in English
| MEDLINE | ID: covidwho-208932
3.
Autoimmun Rev
; 19(7): 102572, 2020 07.
Article
in English
| MEDLINE | ID: covidwho-155059